Form 4: Cartesian Therapeutics Director Michael Singer Reports Acquisition of Stock and Stock Options

Director Michael Singer reports acquiring 2,600 shares of common stock and 7,800 stock options in Cartesian Therapeutics, Inc.

Summary

• On January 2, 2025, Michael Singer, a director of Cartesian Therapeutics, Inc., acquired 2,600 shares of common stock.
• These shares were acquired as restricted stock units, which will vest in full on January 2, 2026.
• Singer also acquired 7,800 stock options with an exercise price of $16.93, exercisable from January 2, 2026, and expiring on January 1, 2035.
• Following these transactions, Singer directly owns 73,533 shares of common stock.
• Singer also has indirect ownership through various trusts and custodial accounts for his spouse and children, totaling 654,878 shares.
• The reporting person's spouse is a trustee of a trust that holds 383,796 shares.
• The reporting person is a trustee of a trust that holds 56,719 shares.
• The reporting person's spouse is a trustee of a trust that holds 7,127 shares.
• The reporting person's spouse holds 14,788 shares.
• The reporting person serves as custodian for two accounts holding 96,219 shares each.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard regulatory filing detailing insider transactions. The acquisition of shares and options could be interpreted as a positive sign, but it's not definitive.

Positives

• The acquisition of stock and stock options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. These filings are monitored by investors to gain insights into management's perspective on the company's value and future prospects.

Comparison to Industry Standards

• Insider transactions are a common occurrence in publicly traded companies like Cartesian Therapeutics.
• Monitoring these transactions is a standard practice for investors to gauge management's sentiment and alignment with shareholder interests.
• Comparing the size and frequency of insider transactions at Cartesian Therapeutics to those of its peers in the biotechnology industry can provide valuable context.

Stakeholder Impact

• The reported transactions may influence investor sentiment regarding the company's prospects.
• The transactions do not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates